{"id":"https://openalex.org/W2892123761","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.e13520","title":"Association analysis of the combination of tumor burden and PD-L1 expression and response to PD-1/L1 inhibitors in Chinese cancer patients.","display_name":"Association analysis of the combination of tumor burden and PD-L1 expression and response to PD-1/L1 inhibitors in Chinese cancer patients.","publication_year":2018,"publication_date":"2018-05-20","ids":{"openalex":"https://openalex.org/W2892123761","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.e13520","mag":"2892123761"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2018.36.15_suppl.e13520","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.e13520","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.e13520","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027784329","display_name":"Kunsong Li","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kunsong Li","raw_affiliation_strings":["Guangdong Second Provixcial General Hospital, Guangzhou, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Guangdong Second Provixcial General Hospital, Guangzhou, China;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044890075","display_name":"Geng Tian","orcid":"https://orcid.org/0000-0001-5752-4436","observed_orcids":["https://orcid.org/0000-0001-5752-4436"]},"institutions":[{"id":"https://openalex.org/I4210164332","display_name":"Shenzhen Second People's Hospital","ror":"https://ror.org/05c74bq69","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210164332"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Geng Tian","raw_affiliation_strings":["Department of Oncology, Shenzhen Second People\u2019s Hospital, Shenzhen, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Shenzhen Second People\u2019s Hospital, Shenzhen, China;","institution_ids":["https://openalex.org/I4210164332"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030309312","display_name":"Senming Wang","orcid":"https://orcid.org/0000-0002-0331-2654","observed_orcids":["https://orcid.org/0000-0002-0331-2654"]},"institutions":[{"id":"https://openalex.org/I58200834","display_name":"Southern Medical University","ror":"https://ror.org/01vjw4z39","country_code":"CN","type":"education","lineage":["https://openalex.org/I58200834"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Senming Wang","raw_affiliation_strings":["Zhujiang Hostital of Southern Medical University, Guangzhou, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Zhujiang Hostital of Southern Medical University, Guangzhou, China;","institution_ids":["https://openalex.org/I58200834"]}]},{"author_position":"middle","author":{"id":null,"display_name":"William Lewis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Lewis","raw_affiliation_strings":["MORE Health, Inc, Foster City, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MORE Health, Inc, Foster City, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067409432","display_name":"Xiaodong Pan","orcid":"https://orcid.org/0000-0001-9511-6986","observed_orcids":["https://orcid.org/0000-0001-9511-6986"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaodong Pan","raw_affiliation_strings":["OrigiMed, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OrigiMed, Shanghai, China;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101558364","display_name":"Xiaowei Dong","orcid":"https://orcid.org/0000-0002-6229-3529","observed_orcids":["https://orcid.org/0000-0002-6229-3529"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"XiaoWei Dong","raw_affiliation_strings":["OrigiMed, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OrigiMed, Shanghai, China;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107988795","display_name":"Dong\u2010Lin Chen","orcid":"https://orcid.org/0009-0003-2494-7215","observed_orcids":["https://orcid.org/0009-0003-2494-7215"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Donglin Chen","raw_affiliation_strings":["OrigiMed, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OrigiMed, Shanghai, China;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101947702","display_name":"Ming Yao","orcid":"https://orcid.org/0000-0002-9293-987X","observed_orcids":["https://orcid.org/0000-0002-9293-987X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ming Yao","raw_affiliation_strings":["OrigiMed, Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OrigiMed, Shanghai, China;","institution_ids":[]}]},{"author_position":"last","author":{"id":null,"display_name":"Kai Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I76130692","display_name":"Zhejiang University","ror":"https://ror.org/00a2xv884","country_code":"CN","type":"education","lineage":["https://openalex.org/I76130692"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Kai Wang","raw_affiliation_strings":["OrigiMed & Zhejiang University International Hospital, China, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OrigiMed & Zhejiang University International Hospital, China, China;","institution_ids":["https://openalex.org/I76130692"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"36","issue":"15_suppl","first_page":"e13520","last_page":"e13520"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tumor-mutational-burden","display_name":"tumor mutational burden","score":0.722000002861023},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pd-1-pd-l1-inhibitors","display_name":"PD-1/PD-L1 inhibitors","score":0.9679999947547913},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9670000076293945},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7960000038146973},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8100000023841858},{"id":"https://openalex.org/keywords/intrahepatic-cholangiocarcinoma","display_name":"intrahepatic cholangiocarcinoma","score":0.9710000157356262},{"id":"https://openalex.org/keywords/hepatocellular-carcinoma","display_name":"hepatocellular carcinoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/gastric-cancer","display_name":"gastric cancer","score":0.9879999756813049},{"id":"https://openalex.org/keywords/durable-clinical-benefit","display_name":"durable clinical benefit","score":0.8529999852180481},{"id":"https://openalex.org/keywords/chinese-cancer-patients","display_name":"Chinese cancer patients","score":0.7200000286102295},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.6650000214576721},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.5809999704360962},{"id":"https://openalex.org/keywords/tumor-genomic-alterations","display_name":"tumor genomic alterations","score":0.32899999618530273}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8759779930114746},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6295844316482544},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.562919020652771},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.560571014881134},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5552529692649841},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.32910656929016113}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2018.36.15_suppl.e13520","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.e13520","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.e13520","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.7900000214576721,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2417822880","https://openalex.org/W628600844","https://openalex.org/W1570838273","https://openalex.org/W2410885201","https://openalex.org/W2385390897","https://openalex.org/W3172842848","https://openalex.org/W2418745692","https://openalex.org/W2404951810","https://openalex.org/W2800415451","https://openalex.org/W2337719538"],"abstract_inverted_index":{"e13520":[0],"Background:":[1],"PD-1/L1":[2,139],"inhibitors":[3,29,140,336],"have":[4],"demonstrated":[5],"their":[6],"remarkable":[7],"clinical":[8,166,207],"efficacy":[9],"in":[10,30,39,92,160,183,243,259,274,285,318,349],"multiple":[11],"tumors.":[12],"PD-L1":[13,109,254,265,286,328,341],"expression":[14,110,266,287],"and":[15,59,89,129,157,186,283,313,327],"tumor":[16,162],"mutation":[17],"burden":[18],"(TMB)":[19],"are":[20,36],"the":[21,82,118,187,196,205,212,223,235,253,256,271,323,331],"most":[22],"studied":[23],"biomarkers":[24],"for":[25,108,136,176,252],"immune":[26,334],"check":[27],"point":[28],"western":[31],"cohort.":[32],"However,":[33],"sufficient":[34],"evidences":[35],"still":[37],"lacking":[38],"Chinese":[40,319,350],"cancer":[41,48,62,87,320,351],"patients":[42,105,133],"(pts).":[43],"Methods:":[44],"Totally":[45],"32":[46,119],"advanced":[47],"pts":[49,120,224,244,261,276,302],"including":[50,126,154],"19":[51],"NSCLC,":[52],"11":[53],"intrahepatic":[54],"cholangiocarcinoma,":[55],"1":[56,60],"hepatocellular":[57],"carcinoma":[58],"gastric":[61],"who":[63],"received":[64],"anti-PD-1/PD-L1":[65],"treatment":[66],"as":[67,172],"multi-line":[68],"therapies":[69,317],"were":[70,74,106,134],"recruited.":[71],"Genomic":[72],"alterations":[73],"assayed":[75],"by":[76,98,111],"deep":[77],"sequencing":[78],"panel":[79],"assay":[80],"targeting":[81],"whole":[83],"exons":[84],"of":[85,117,195,222,299,315,325,333],"450":[86],"genes":[88],"selected":[90,104],"introns":[91],"39":[93],"genes.":[94],"TMB":[95,194,214,226,246,278,312,339],"was":[96,121,152,170,181,190,199,267,288],"acquired":[97],"NGS":[99],"algorithm.":[100],"Tumor":[101],"tissues":[102],"from":[103,234],"analyzed":[107],"IHC.":[112],"Results:":[113],"The":[114,148,192,237],"median":[115,193,213],"age":[116],"53.5":[122],"years":[123],"(range:":[124,202,219],"35-69)":[125],"23":[127],"males":[128],"9":[130],"females.":[131],"These":[132],"administrated":[135],"FDA":[137],"approved":[138],"with":[141,225,245,262,277],"or":[142,145,174,340],"without":[143],"chemo":[144],"antiangiogenesis":[146],"therapies.":[147],"overall":[149],"response":[150,314,332],"rate":[151,189,239,258,273],"43.8%,":[153],"one":[155],"CR":[156],"13":[158],"PR":[159],"multi":[161],"types.":[163],"Moreover,":[164,322],"durable":[165],"benefits":[167,208],"(DCB)":[168],"which":[169],"defined":[171],"CR/PR":[173],"SD":[175],"at":[177,216],"least":[178],"6":[179],"months":[180],"observed":[182],"21":[184],"pts,":[185],"DCB":[188,197,233,238,257,272],"65.6%.":[191],"group":[198,210],"15.5":[200],"muts/Mb":[201,218,231,282],"3.2-369),":[203],"but":[204],"no":[206],"(NCB)":[209],"had":[211],"value":[215,227],"9.3":[217],"0.8-19).":[220],"All":[221],"greater":[228,247,279],"than":[229,248,280,338],"20":[230],"achieved":[232],"treatment.":[236],"dropped":[240],"to":[241],"72.7%":[242],"10":[249,281],"muts/MB.":[250],"As":[251],"expression,":[255],"14":[260],"positive":[263,284,329],"tumorous":[264],"71.4%.":[268],"In":[269],"addition,":[270],"8":[275],"100%.":[289],"Conclusions:":[290],"Our":[291],"preliminary":[292],"results":[293],"based":[294],"on":[295],"a":[296,304],"small":[297],"number":[298],"real":[300],"world":[301],"showed":[303],"significant":[305],"association":[306],"(p":[307],"=":[308],"0.0048)":[309],"between":[310],"high":[311],"anti-PD-1/L1":[316],"pts.":[321,352],"combination":[324],"TMB-H":[326],"predicted":[330],"checkpoint":[335],"better":[337],"along.":[342],"Further":[343],"larger":[344],"cohort":[345],"study":[346],"is":[347],"warranted":[348]},"counts_by_year":[],"updated_date":"2026-10-13T10:08:12.033832","created_date":"2025-10-10T00:00:00"}